Keyword: Principia Biopharma
AbbVie and Principia are ending an autoimmunity-focused deal, with Principia regaining the rights to the immunoproteasome inhibitor program.
Principia has started a phase 3 program for its BTK inhibitor in the autoimmune disease pemphigus after hitting the target in a midstage trial.
Principia Biopharma has filed to raise up to $86.3 million in its IPO to carry its lead BTK inhibitor into phase 3.
Evobrutinib cut gadolinium-enhancing T1 lesions by more than placebo, but Merck has yet to quantify the difference or say if it beat Tecfidera.